The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma.
 
Daniel H. Palmer
Honoraria - Bayer Schering Pharma; Boehringer Ingelheim; Celgene; Targovax
Consulting or Advisory Role - Bayer; Celgene
Speakers' Bureau - Bayer
Research Funding - Bayer (Inst)
 
Svein Dueland
No Relationships to Disclose
 
Juan W. Valle
Honoraria - AstraZeneca; Celgene; Ipsen; Novartis; Pfizer
Consulting or Advisory Role - Celgene
Research Funding - AstraZeneca (Inst); Novartis (Inst)
 
Tone Otterhaug
No Relationships to Disclose
 
Jon Amund Eriksen
Employment - Targovax
Leadership - Targovax
Stock and Other Ownership Interests - Targovax
Honoraria - Targovax
Research Funding - Targovax
Patents, Royalties, Other Intellectual Property - Targovax
 
Helene Muller
No Relationships to Disclose
 
Berit Iversen
Employment - Targovax
Leadership - Targovax
 
Robert M. Miller
Consulting or Advisory Role - Atcor (Inst); Lytix Biopharma (Inst); Nerre Therapeutics (Inst); Opsona Therapeutics (Inst); Steba Biotech (Inst); Targovax (Inst)